Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16786041 | 0.89 | SLC18A3 (0.50) | SLC18A3TP53GRIN2BLIPECYP2D6 | |
| SCHEMBL16437277 | 0.86 | TP53 (0.43) | SLC18A3TP53GRIN2BTLR9TLR8 | |
| SCHEMBL16786040 | 0.86 | SLC18A3 (0.56) | SLC18A3TP53GRIN2BLIPECYP2D6 | |
| SCHEMBL4404291 | 0.86 | SLC18A3 (0.60) | SLC18A3TP53GRIN2BCYP2D6CYP2C19 | |
| SCHEMBL4402787 | 0.84 | SLC6A2 (0.44) | TP53LIPESIGMAR1HRH3MAPT | |
| SCHEMBL17850380 | 0.83 | SLC18A3 (0.53) | SLC18A3GRIN2BTLR9TLR8TLR7 | |
| SCHEMBL31222854 | 0.80 | SLC18A3 (0.47) | SLC18A3GRIN2BTLR9TLR8TLR7 | |
| SCHEMBL4483396 | 0.79 | SLC18A3 (0.69) | SLC18A3GRIN2BCYP2D6CYP2C19SIGMAR1 | |
| SCHEMBL20234318 | 0.79 | TP53 (0.42) | SLC18A3TP53GRIN2BLIPECYP2D6 | |
| SCHEMBL4404601 | 0.76 | CNR2 (0.61) | TLR9TLR8TLR7LIPEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | SLC18A3 4344/4885TP53 2899/4885GRIN2B 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.